Plaque psoriasis is a chronic autoimmune skin disorder characterized by red, scaly patches that commonly appear on the scalp, elbows, and knees. As per Hayidar Lubwama et al. (2025), psoriasis affects 1-3% of the global population, with prevalence rates ranging from 0.09% to 11.43% across regions. According to the Plaque Psoriasis Pipeline Analysis by Expert Market Research, the market is witnessing significant growth driven by the rising adoption of biologics, targeted immunomodulators, and small-molecule inhibitors. The growing research focus on novel biologic agents and personalized therapies is expected to drive substantial improvements in treatment efficacy over the coming years.
The Plaque Psoriasis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into plaque psoriasis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for plaque psoriasis. The plaque psoriasis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The plaque psoriasis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with plaque psoriasis treatment guidelines to ensure optimal care practices.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing plaque psoriasis pipeline development activities are covered. Moreover, plaque psoriasis collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Read more about this report - Request a Free Sample
Plaque psoriasis or psoriasis vulgaris is a chronic autoimmune disorder that causes cells to reproduce very quickly. The most common affected areas are elbows, back, knees and scalp among others. Plaque psoriasis is an immune disorder wherein the immune response overreacts, causing inflammation and leading to the rapid growth of new skin cells. New skin cells grow every 28-30 days, but in people suffering from plaque psoriasis, new cells grow and move to the skin's surface every 3-4 days. The buildup of new cells replacing old cells creates plaques. The disease can affect anyone, however, the white population is more prone to the condition. The symptoms of plaque psoriasis include the appearance of raised, discolored plaques with a white or silvery surface, bleeding, cracks, itchiness and irritation or pain among others.
To treat plague psoriasis with mild symptoms, creams, lotion, or gel such as anthralin, coal tar, corticosteroids, salicylic acid are commonly prescribed. In severe cases, healthcare providers may recommend medicinal injections such as adalimumab, etanercept or Ustekinumab, or oral medicines such as acitretin, cyclosporine or methotrexate. Depending on the patient profile, procedures like phototherapy can also be advised. It uses ultraviolet light, usually ultraviolet B from special lamps. Moreover, several companies and institutes are developing novel therapies to manage the disease. For instance, a trial is investigating whether people with plaque psoriasis can take an oral treatment to manage and improve the condition. The presence of large clinical trials for plaque psoriasis has influenced the pipeline landscape positively.
This section of the report covers the analysis of plaque psoriasis drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s plaque psoriasis therapeutics assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for plaque psoriasis with 278 pipeline drugs in phase III.
The drug molecules categories covered under plaque psoriasis pipeline analysis include antibody, antisense oligonucleotides, immunotherapy, monoclonal antibody, peptides, protein, recombinant protein, small molecule, stem cell and vaccine. Several trials are ongoing to assess the efficacy of immunotherapies. Studies show that targeted biological immunotherapies have been highly effective in controlling skin disease in patients with psoriasis. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for plaque psoriasis.
The EMR plaque psoriasis drug report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in plaque psoriasis clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for plaque psoriasis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of plaque psoriasis drug candidates.
The trial is designed to investigate the clinical efficacy of EDP1815 and to identify an optimal dose in people with mild to moderate psoriasis. The trial is sponsored by Evelo Biosciences Inc. and is currently under phase II.
The objective of the study is to assess the safety and tolerability of AX-158 in patients with mild to moderate psoriasis. The trial is sponsored by Artax Biopharma Inc. and is currently under phase II.
Galderma R&D is developing the drug and is currently under phase IV. The study is being designed to evaluate the efficacy of a topical skincare regimen conducted at 2 weeks, 4 weeks, and 8 weeks post-baseline.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Plaque psoriasis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for plaque psoriasis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into plaque psoriasis collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
Psoriatic Arthritis Treatment Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share